Testosterone replacement therapy (TRT) can raise PSA (prostate-specific antigen) levels, but a modest, predictable increase is the expected response, not a warning sign on its own. What matters clinically is the size and speed of the change: a PSA rise of more than 1.4 ng/mL within a year, or a level that crosses the age-adjusted threshold (typically 4.0 ng/mL), is what prompts further evaluation. Because PSA is one of the core labs used to monitor prostate safety on testosterone therapy, alongside hematocrit and estradiol, knowing what counts as a normal PSA response to TRT, versus a red flag, is essential before and during treatment.
How Does Testosterone Therapy Affect PSA Levels?
PSA is produced by prostate epithelial cells, and testosterone (through its conversion to DHT) helps regulate how active that tissue is. Men with untreated low testosterone often have prostate tissue that is relatively understimulated, which can suppress PSA output below what it would be at normal hormone levels. When TRT restores testosterone into the physiologic range, prostate tissue activity — and PSA — typically rises to match, then plateaus. This is sometimes called the “PSA saturation model”: once androgen receptors in the prostate are saturated, which clinical studies suggest happens at relatively low testosterone concentrations, further increases in testosterone produce little additional PSA change. That’s why most men see PSA rise modestly in the first six to twelve months of TRT and then stabilize, rather than climb indefinitely.
What Counts as a Normal PSA Increase on TRT?
Clinical data generally shows an average PSA increase of about 0.3 to 0.5 ng/mL during the first year of testosterone therapy, with the total typically remaining well within the normal range for a man’s age (commonly under 4.0 ng/mL for men under 60, with age-adjusted ranges used for older men). Some patients report no measurable change at all. A single elevated reading also isn’t automatically meaningful — PSA can fluctuate due to recent ejaculation, a urinary tract infection, prolonged bike riding, or lab variability, so an unexpected result is usually confirmed with a repeat test before any decisions are made.
PSA Velocity Matters More Than the Number Alone
Providers watch PSA velocity — the rate of change over time — as closely as the absolute value. A rise of more than 1.4 ng/mL in a 12-month period is a widely used trigger for further workup, even if the resulting PSA is still technically within the normal range. This is why baseline testing before starting TRT matters: without a starting point, it’s impossible to calculate velocity accurately or tell a genuine trend from normal lab noise.
When a Rising PSA on TRT Is a Red Flag
A few patterns warrant pausing therapy and getting a urology referral: a PSA velocity above 1.4 ng/mL per year, an absolute PSA that crosses the age-adjusted threshold, an abnormal digital rectal exam finding, or a strong family history of prostate cancer combined with any upward trend. In these cases, a provider may order a free-to-total PSA ratio, an MRI, or refer for further evaluation before resuming testosterone therapy. Current evidence does not show that TRT causes prostate cancer in men without pre-existing disease, but because androgens can accelerate the growth of an undetected cancer, the screening protocol exists specifically to catch that scenario early rather than to discourage appropriate treatment of low testosterone.
PSA Testing Schedule While on Testosterone Therapy
A typical monitoring schedule includes a baseline PSA (and often a digital rectal exam) before starting TRT, especially for men over 40 or with prostate cancer risk factors, a follow-up PSA at three to six months to establish the early trend, and annual PSA testing thereafter for as long as therapy continues. This runs alongside the other labs used to monitor TRT safety, including hematocrit (to catch thickened blood) and estradiol or SHBG (to understand how testosterone is being used and converted in the body). Skipping baseline testing is one of the more common gaps in self-directed or poorly supervised TRT, and it’s exactly what makes a later PSA change hard to interpret.
Frequently Asked Questions
Does testosterone therapy cause prostate cancer?
Current evidence does not show that TRT causes prostate cancer in men without pre-existing disease. The clinical concern is different: androgens may accelerate the growth of a cancer that is already present but undetected, which is why baseline and follow-up PSA screening is a standard part of TRT protocols rather than an optional extra.
Should I stop TRT if my PSA goes up?
A modest, expected rise — generally under 1.4 ng/mL over a year and still within the normal range for your age — is not usually a reason to stop treatment. A faster rise, a level crossing the age-adjusted threshold, or an abnormal exam finding is what typically prompts a pause and a urology referral.
How often should men on TRT get a PSA test?
Most protocols call for a baseline PSA before starting therapy, a follow-up test at three to six months, and annual testing after that. Men with additional prostate cancer risk factors, such as family history, may be monitored more closely.
Monitoring PSA is a normal, manageable part of testosterone therapy, not a reason to avoid it. RespondWell’s TRT programs include baseline and ongoing lab work as part of treatment, so changes get caught early and addressed with your provider rather than discovered after the fact. If you’re considering testosterone therapy or want your current TRT protocol reviewed with proper lab monitoring, you can get started at RespondWell.